Engineering heavy chain antibody‐drug conjugates against solid tumors for a one‐shot kill

Engineering heavy chain antibody‐drug conjugates against solid tumors for a one‐shot kill

Saved in:

Bibliographic Details
Main Authors:	Xue Liu, Wenjing Ning, Lei Wang, Han Liu, Hongye Zeng, Xiaojing Qin, Yuanzhi Chen, Fentian Chen, Lin Xu, Yang Zhao, Xiaoqing Chen, Jixian Tang, Yunlong Ren, Xiaowen Yan, Wenxin Luo, Ningshao Xia
Format:	Article
Language:	English
Published:	Wiley 2024-12-01
Series:	Cancer Communications
Online Access:	https://doi.org/10.1002/cac2.12616
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Antibody-Drug Conjugates in Solid Tumors
by: Ilaria Colombo, et al.
Published: (2022-03-01)

Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates
by: Oliver Kepp, et al.
Published: (2025-12-01)

Editorial: Antibody-drug conjugates in solid and hematologic malignancies
by: Khalil Saleh, et al.
Published: (2025-08-01)

Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis
by: Wenjun Fang, et al.
Published: (2025-12-01)

Enhancing Tumor Immunity with IL-12 and PD-1 Blockade: A Strategy for Inducing Robust Central Memory T Cell Responses in Resistant Cancer Model
by: Fentian Chen, et al.
Published: (2024-11-01)

SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles
by: Ting Zhang, et al.
Published: (2025-01-01)

SHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles.
by: Ting Zhang, et al.
Published: (2025-01-01)

Antibody drug conjugates
by: Stalin Bala, et al.
Published: (2020-01-01)

Interrogating heterogeneity of cysteine-engineered antibody-drug conjugates and antibody-oligonucleotide conjugates by capillary zone electrophoresis-mass spectrometry
by: Tian Xu, et al.
Published: (2023-12-01)

Diverse Roles of Antibodies in Antibody–Drug Conjugates
by: Aiko Yamaguchi, et al.
Published: (2025-01-01)

Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age
by: Yi Liu, et al.
Published: (2025-12-01)

The Impact of Conjugation Mode and Site on Tubulysin Antibody‐Drug‐Conjugate Efficacy and Stability
by: Sayumi Yamazoe, et al.
Published: (2025-08-01)

Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024-11-01)

Antibody-Drug Conjugates in Cancer
by: Marcus Vetter
Published: (2024-06-01)

Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
by: Ruili Wang, et al.
Published: (2025-04-01)

Trispecific SEED antibodies engineered for neutrophil-mediated cell killing
by: Veronica Natale, et al.
Published: (2025-12-01)

Mesothelin-directed protein-drug conjugates for mesothelin-low solid tumor therapy
by: Ying Wang, et al.
Published: (2025-08-01)

Current progress and remaining challenges of peptide–drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?
by: Dongyuan Wang, et al.
Published: (2025-04-01)

Design, Synthesis, and Evaluation of Camptothecin-Based Antibody–Drug Conjugates with High Hydrophilicity and Structural Stability
by: Tingyu Xiong, et al.
Published: (2025-03-01)

Development of a bispecific antibody–drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors
by: Meiying Luo, et al.
Published: (2025-03-01)

Constructions, Purifications and Applications of DNA-Antibody Conjugates: A Review
by: Tao Wang, et al.
Published: (2024-11-01)

Current issues with antibody-conjugated lipid nanoparticles
by: Aayush
Published: (2025-02-01)

Advancements in antibody-drug conjugates as cancer therapeutics
by: Jung Yin Fong, et al.
Published: (2025-08-01)

Therapeutic index improvement of antibody-drug conjugates
by: Hans-Peter Gerber, et al.
Published: (2023-12-01)

Exploration of the antibody–drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023-12-01)

Resistance to antibody–drug conjugates: A review
by: Sijia Li, et al.
Published: (2025-02-01)

Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations
by: Jiang Liu, et al.
Published: (2025-05-01)

Cancer-oocyte SAS1B protein is expressed at the cell surface of multiple solid tumors and targeted with antibody-drug conjugates
by: Craig L Slingluff, et al.
Published: (2024-03-01)

Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors
by: Yi-Chiu Kuo, et al.
Published: (2025-07-01)

Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
by: Yangyang Gao, et al.
Published: (2025-01-01)

Antibody-drug conjugates in breast cancer: advances and prospects
by: Zhiqiang Shi, et al.
Published: (2025-02-01)

AI-driven innovation in antibody-drug conjugate design
by: Heather A. Noriega, et al.
Published: (2025-06-01)

Antibody-Drug Conjugates in Ovarian Cancer: Promises and Challenges
by: Marta Nerone, et al.
Published: (2023-10-01)

Preparation of Antibody-Conjugated Gold Nanotriangles for Immunochromatographic Test
by: Asahi Kimura, et al.
Published: (2024-03-01)

Clinical advances in antibody-drug conjugates for hematological malignancies
by: TANG Sijie, et al.
Published: (2024-12-01)

A Phosphatidyl Conjugated Telomerase-Dependent Telomere-Targeting Nucleoside Demonstrates Colorectal Cancer Direct Killing and Immune Signaling
by: Merve Yilmaz, et al.
Published: (2024-12-01)

Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48
by: Xin Gao, et al.
Published: (2025-08-01)

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis
by: Heng Chen, et al.
Published: (2024-12-01)

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
by: Christine Ambrose, et al.
Published: (2021-01-01)

Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates
by: Qingling Yin, et al.
Published: (2025-04-01)